In a 45-year-old HIV-positive man with a positive tuberculin skin test >14 mm after exposure to a tuberculosis case and a normal chest radiograph, what is the appropriate anti‑tuberculosis treatment regimen?

Treatment Recommendation for Latent TB in HIV-Positive Patient

This HIV-positive patient with a positive TST (>14 mm) and normal chest X-ray should receive isoniazid monotherapy for 9 months (Option B: 2 Anti-TB treatment for 9 months). 1

Rationale and Evidence

The American Thoracic Society/CDC guidelines explicitly recommend isoniazid for 9 months as the preferred regimen (Grade A-II recommendation) for HIV-positive individuals with latent tuberculosis infection (LTBI) 1. This represents the highest-quality recommendation for this specific population.

Key Treatment Details:

• Regimen: Isoniazid 300 mg daily for 9 months
• Alternative dosing: Twice-weekly dosing is acceptable (Grade B-II) but requires directly observed therapy (DOT) 1
• Why 9 months specifically: While 12-month regimens show maximal benefit, subgroup analyses demonstrate that 9 months achieves nearly equivalent protection with improved completion rates 1

Why Not the Other Options:

Option A (No treatment) is incorrect because:

• TST >14 mm is definitively positive in HIV patients (cutoff is ≥5 mm for this population) 1
• Preventive therapy reduces active TB incidence by 62% in TST-positive HIV patients (RR 0.38,95% CI 0.25-0.57) 2
• HIV patients have substantially higher risk of progression from latent to active TB 3

Option C (2 drugs for 9 months) is incorrect because:

• This doesn't match any standard LTBI regimen
• Two-drug regimens (rifampin-pyrazinamide) are recommended for only 2 months, not 9 1

Option D (4 drugs for 4 months, then 2 for 2 months) is incorrect because:

• This describes treatment for active TB disease, not latent infection
• The patient has a normal chest X-ray and no evidence of active disease

Alternative Acceptable Regimens

While isoniazid for 9 months is preferred, the guidelines also recognize:

• Rifampin + pyrazinamide for 2 months (Grade A-I for HIV-positive) 1 - though this has higher toxicity risk
• Rifampin alone for 4 months (Grade B-II) - useful if isoniazid cannot be tolerated 1
• Isoniazid for 6 months (Grade C-I for HIV-positive) - provides substantial but suboptimal protection 1

Critical Pre-Treatment Steps

Before initiating treatment, active TB must be excluded through:

• Clinical symptom assessment (cough, fever, night sweats, weight loss)
• Chest radiography (already done - normal)
• Sputum cultures if any symptoms present 1

Important Caveats

Drug interactions: If the patient is on antiretroviral therapy with protease inhibitors, rifampin-based regimens require careful consideration due to significant drug-drug interactions. Rifabutin may be substituted 1.

Monitoring: Baseline and periodic liver function tests are essential, as HIV-positive patients may have higher rates of adverse drug reactions 4.

TST sensitivity: Note that TST sensitivity decreases with lower CD4 counts, but a positive result remains highly predictive of benefit from preventive therapy 5, 6.